Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bifidobacterium,Lactobacillus Rhamnosus
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kids Chewable probiotic supplements, TruBiotics (Bifidobacterium) and Lactobacillus launched by company, the two most-clinically researched probiotic types to support digestive and immune heath for children.
Product Name : TruBiotics
Product Type : Microorganism
Upfront Cash : Inapplicable
February 03, 2022
Lead Product(s) : Bifidobacterium,Lactobacillus Rhamnosus
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Rhamnosus,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : Lactobacillus Rhamnosus,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Paracasei,Lactobacillus Rhamnosus,L-Arginine
Therapeutic Area : Dental and Oral Health
Study Phase : Undisclosed
Sponsor : University of Copenhagen
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of 12 Months Supplementation With a Symbiotic Lozenge on Caries Increment in Healthy Children
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
April 26, 2019
Lead Product(s) : Lactobacillus Paracasei,Lactobacillus Rhamnosus,L-Arginine
Therapeutic Area : Dental and Oral Health
Highest Development Status : Undisclosed
Sponsor : University of Copenhagen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Rhamnosus,Bifidobacterium Animalis Subsp. Lactis
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Sprim Advanced Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
November 09, 2012
Lead Product(s) : Lactobacillus Rhamnosus,Bifidobacterium Animalis Subsp. Lactis
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Sprim Advanced Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L. Acidophilus,Lactobacillus Casei,Lactobacillus Rhamnosus
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Sprim Advanced Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 06, 2012
Lead Product(s) : L. Acidophilus,Lactobacillus Casei,Lactobacillus Rhamnosus
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Sprim Advanced Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable